Status:
UNKNOWN
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Tyrosine Kinase Inhibitor
Pharmacokinetics
Eligibility:
All Genders
20+ years
Brief Summary
Chronic myeloid leukemia (CML) consists of 3 clinical stages including chronic phase, accelerated phase and blast crisis. Patients may only survive for few more days to weeks once the disease progress...
Eligibility Criteria
Inclusion
- Adult patients (≥ 20 year-old)
- Patients who meet the above criteria and have already initiated or are going to receive imatinib, dasatinib, nilotinib, or ponatinib treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from September 2022 to December 2025
Exclusion
- Patients who are unable to cooperate with blood drawing
- Patients who have not submit the informed consent
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05259228
Start Date
December 1 2022
End Date
December 1 2025
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100